Overview

Cranoc Lipid Study in Renal Transplantation

Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Cardiovascular disease after renal transplantation is an important problem. Patients after renal transplantation with low LDL-Levels (<130mg/dl) receive Fluvastatin 80mg/day (or no medication, to look for the cardiovascular outcome with and without statins.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University Hospital Schleswig-Holstein
University of Schleswig-Holstein
Treatments:
Fluvastatin